Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26.
Zydus Lifesciences reported a rise in reported net profit for Q4FY26, despite a sharp increase in one-off expenses, as strong operational performance and margin expansion cushioned the impact of exceptional items.
The company posted a reported net profit of Rs 1272.5 crore, up 8.7 percent year-on-year, while adjusted net profit rose 15 percent to Rs 1592.9 crore, reflecting underlying strength across key businesses.
The divergence between reported and adjusted profit was driven by a Rs 397.5 crore one-time expense related to a Mirabegron litigation settlement, alongside other exceptional costs during the quarter.
Zydus board approved a buyback of up to Rs 1100 crore at Rs 1,150 per share, along with a 100 percent dividend for FY26.
Revenue from operations rose 16 percent year-on-year to Rs 7587 crore, while EBITDA grew faster at 20 percent, expanding margins by 110 basis points to 33.7 percent.
The margin improvement came despite elevated investments—particularly in R&D, which rose to 9.2 percent of revenue—and higher operating costs, indicating stronger gross performance and operating leverage.
“We closed FY26 on a strong note, delivering on our commitments—both on revenue growth and profitability,” Managing Director Sharvil Patel said, adding that the company’s pipeline and growth engines would support future visibility.
Growth was led by a mix of domestic formulations, consumer wellness and international markets.
India formulations grew 14 percent year-on-year to Rs 1752.8 crore, continuing to outpace the broader market, led by chronic therapies and specialty segments such as oncology and nephrology.
International markets surged 45 percent to Rs.804 crore, driven by demand across emerging markets and Europe.
Consumer wellness stood out with a sharp 61 percent jump, aided by strong performance in international business and select categories like skin and nutrition.
However, growth in the core US generics business remained muted. North America formulations declined 6 percent year-on-year, reflecting pricing pressure, even as sequential growth was supported by new launches and base business traction.
The investor presentation underscored Zydus’ pivot toward diversified growth engines beyond generics, including consumer health, specialty pharmaceuticals and MedTech.
Consumer wellness now contributes about 20 percent of revenues, while MedTech—still small—has begun scaling. In the US, the company is pushing deeper into specialty and rare disease segments, including the planned acquisition of Assertio Holdings and expansion of the 505(b)(2) pipeline.
At the same time, Zydus continues to invest aggressively in innovation, with ongoing biosimilar launches, novel drug development and global filings, reinforcing its transition toward a research-led model.
Patel emphasised capital discipline alongside growth ambitions: “Our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further.”
Share of Zydus rose 2.80 percent to Rs 1018.95 at 3.50 pm on BSE on Tuesday, while the benchmark Sensex declined 0.15 percent to 75,200 points.
